FRAGOMENO, BENEDETTA
 Distribuzione geografica
Continente #
NA - Nord America 115
EU - Europa 114
AS - Asia 47
AF - Africa 13
OC - Oceania 3
Totale 292
Nazione #
US - Stati Uniti d'America 115
IT - Italia 42
SG - Singapore 19
DE - Germania 18
SE - Svezia 16
CN - Cina 10
CH - Svizzera 9
IN - India 9
GB - Regno Unito 7
CI - Costa d'Avorio 6
JO - Giordania 5
RU - Federazione Russa 5
TG - Togo 5
ES - Italia 4
IE - Irlanda 4
AU - Australia 3
FI - Finlandia 3
BG - Bulgaria 2
JP - Giappone 2
NG - Nigeria 2
BE - Belgio 1
FR - Francia 1
KR - Corea 1
PL - Polonia 1
RO - Romania 1
VN - Vietnam 1
Totale 292
Città #
Chandler 19
Singapore 17
Santa Clara 14
Bern 9
Ashburn 8
Southend 7
Turin 7
Abidjan 6
Boardman 6
Florence 6
Milan 6
Seattle 6
Amman 5
Fairfield 5
Lomé 5
Princeton 5
Dublin 4
Seville 4
Boydton 3
Helsinki 3
San Jose 3
Woodbridge 3
Abeokuta 2
Ann Arbor 2
Berlin 2
Bremen 2
Brescia 2
Hyderabad 2
Melbourne 2
New York 2
Noicattaro 2
Saitama 2
Sofia 2
Bologna 1
Brussels 1
Cambridge 1
Canberra 1
Chicago 1
Council Bluffs 1
Des Moines 1
Hamburg 1
Hanoi 1
Harbin 1
Houston 1
Jinan 1
Magdeburg 1
Magenta 1
Munich 1
Olalla 1
Pavia 1
Phoenix 1
Ravenna 1
Redmond 1
San Francisco 1
Shenyang 1
Sibiu 1
Suzhou 1
Wenzhou 1
Wuhan 1
Yueqing 1
Totale 200
Nome #
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data 124
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors 73
Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab. 62
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents 26
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis 18
Totale 303
Categoria #
all - tutte 1.241
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.241


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202122 0 0 0 0 10 0 0 0 5 2 2 3
2021/202265 0 2 2 0 6 1 4 20 2 5 12 11
2022/2023123 10 19 6 9 12 4 7 10 23 0 12 11
2023/202433 4 5 2 3 0 6 0 7 0 3 1 2
2024/202560 11 11 6 9 20 3 0 0 0 0 0 0
Totale 303